TherapeuticsMD (TXMD) Consolidated Net Income (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Consolidated Net Income came in at $155000.0 in Q2 2026, down 71.87% on a YoY basis from $551000.0 in Q2 2025, and up 63.16% quarter-over-quarter from $95000.0 in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) Consolidated Net Income (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported Consolidated Net Income for 17 consecutive years, with $155000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Consolidated Net Income fell 71.87% year-over-year to $155000.0; the trailing twelve-month figure through Jun 2026 stood at -$185000.0 (up 37.29% YoY), and the FY2025 full-year result was -$569000.0, up 73.91% from the prior year.
- Consolidated Net Income rose to $155000.0 in Q2 2026 per TXMD's latest filing, from $95000.0 in the prior quarter.
- Across five years, Consolidated Net Income topped out at $111.7 million in Q2 2022 and bottomed at -$49.0 million in Q1 2022.
- Historically, Consolidated Net Income has averaged $5.5 million across 5 years, with a median of -$631000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income soared 361.84% in 2022, then slumped 241.11% in 2025.
- Over 5 years, Consolidated Net Income stood at $77.7 million in 2022, then sank by 101.19% to -$926000.0 in 2023, then soared by 144.92% to $416000.0 in 2024, then plunged by 241.11% to -$587000.0 in 2025, then soared by 126.41% to $155000.0 in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered $155000.0, $95000.0, and -$587000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 3.32 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 2.16 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -644.37 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 237.01 Mn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 155,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 155,000.00 |
| Mar 31, 2026 | 95,000.00 |
| Dec 31, 2025 | -587,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 551,000.00 |
| Mar 31, 2025 | -653,000.00 |
| Dec 31, 2024 | 416,000.00 |
| Sep 30, 2024 | -609,000.00 |
| Jun 30, 2024 | -1.16 Mn |
| Mar 31, 2024 | -734,000.00 |
| Dec 31, 2023 | -926,000.00 |
| Sep 30, 2023 | -3.38 Mn |
| Jun 30, 2023 | -2.41 Mn |
| Mar 31, 2023 | -3.60 Mn |
| Dec 31, 2022 | 77.70 Mn |
| Sep 30, 2022 | -28.67 Mn |
| Jun 30, 2022 | 111.68 Mn |
| Mar 31, 2022 | -49.02 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |